[1]Manns MP, Czaja AJ, Gorham JD, et al.Diagnosis andmanagement of autoimmune hepatitis[J].Hepatology, 2010, 51 (6) :2193-2213.
|
[2]Lindor KD, Gershwin ME, Poupon R, et al.Primary biliarycirrhosis[J].Hepatology, 2009, 50 (1) :291-308.
|
[3]Ghonaim M, Al-Ghamdi A, El-Bana H, et al.Autoantibod-ies in chronic liver disease[J].Egypt J Immunol, 2005, 12 (2) :101-111.
|
[4]Invernizzi P, Selmi C, Ranftler C, et al.Antinuclear antibod-ies in primary biliary cirrhosis[J].Semin Liver Dis, 2005, 25 (3) :298-310.
|
[5]Ishibashi H, Komori A, Shimoda S, et al.Guidelines for ther-apy of autoimmune liver disease[J].Semin Liver Dis, 2007, 27 (2) :214-226.
|
[6]Janowitz P, Kratzer W, Wechsler J G.Positive effect of ur-sodeoxycholic acid on liver enzymes in autoimmune hepatitiswith little activity-a pilot study[J].Leber Magen Darm, 1996, 26 (6) :310-313.
|
[7]Miyake Y, Iwasaki Y, Kobashi H, et al.Efficacy of ursode-oxycholic acid for Japanese patients with autoimmune hepati-tis[J].Hepatol Int, 2009, 3 (4) , 556-562.
|
[8]Czaja AJ, Carpenter HA, Lindor KD.Ursodeoxycholic acid asadjunctive therapy for problematic type 1 autoimmune hepati-tis:a randomized placebo-controlled treatment trial[J].Hepatology, 1999, 30 (6) :1381-1386.
|
1. | 陆晖,谭可平,陈婵,覃国琦,陆鹏. 乙型肝炎肝硬化患者肠道菌群水平与TC、TG、HDL-C及LDL-C水平的关系分析. 中国医药科学. 2025(01): 19-22 . ![]() |